Literature DB >> 22610477

Inhaled hypertonic saline in infants and young children with cystic fibrosis.

Elliott C Dasenbrook, Michael W Konstan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22610477      PMCID： PMC4255264          DOI： 10.1001/jama.2012.5853

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  15 in total

1.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

Review 2.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

3.  Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.

Authors:  Stephanie D Davis; Margaret Rosenfeld; Gwendolyn S Kerby; Lyndia Brumback; Margaret H Kloster; James D Acton; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie L Wilcox; Robert G Castile
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

4.  Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.

Authors:  Lauren S Mott; Judy Park; Conor P Murray; Catherine L Gangell; Nicholas H de Klerk; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan; Peter D Sly; Stephen M Stick
Journal:  Thorax       Date:  2011-12-26       Impact factor: 9.139

5.  Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.

Authors:  Margaret Rosenfeld; Felix Ratjen; Lyndia Brumback; Stephen Daniel; Ron Rowbotham; Sharon McNamara; Robin Johnson; Richard Kronmal; Stephanie D Davis
Journal:  JAMA       Date:  2012-06-06       Impact factor: 56.272

6.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

7.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

Authors:  Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

8.  Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.

Authors:  Yvonne Belessis; Barbara Dixon; Glenn Hawkins; John Pereira; Jenny Peat; Rebecca MacDonald; Penny Field; Andrew Numa; John Morton; Kei Lui; Adam Jaffe
Journal:  Am J Respir Crit Care Med       Date:  2012-02-09       Impact factor: 21.405

9.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

Review 10.  Nebulised hypertonic saline for cystic fibrosis.

Authors:  Peter Wark; Vanessa M McDonald
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more
  4 in total

1.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Anil Chauhan; Nikita Jaiswal
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

2.  Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients.

Authors:  Shannon B Donnola; Elliott C Dasenbrook; David Weaver; Lan Lu; Karishma Gupta; Anjali Prabhakaran; Xin Yu; James F Chmiel; Kimberly McBennett; Michael W Konstan; Mitchell L Drumm; Chris A Flask
Journal:  J Cyst Fibros       Date:  2015-12-22       Impact factor: 5.482

Review 3.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Kiran K Thumburu
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

4.  Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients--a cross-sectional study.

Authors:  Elliott C Dasenbrook; Lan Lu; Shannon Donnola; David E Weaver; Vikas Gulani; Peter M Jakob; Michael W Konstan; Chris A Flask
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.